The weekly litigation news digest is live. Subscribe now

IP Verse

Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-Vegf

Patent No. EP3384049 (titled "Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-Vegf") was filed by Regeneron Pharmaceuticals on Dec 1, 2016. The application was issued on Aug 2, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOULT WADE TENNANTMay 1, 2024BOULT WADE TENNANT
POHLMANApr 30, 2024POHLMAN
WUESTHOFF & WUESTHOFFApr 24, 2024WICHMANN
AMGENApr 22, 2024UEXKULL & STOLBERG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3384049

REGENERON PHARMACEUTICALS
Application Number
EP16823372A
Filing Date
Dec 1, 2016
Status
Granted And Under Opposition
Jun 30, 2023
Publication Date
Aug 2, 2023
External Links
Slate, EP3384049B1, Google Patents